Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Drug Profile

Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Alternative Names: Fluzone HD; Fluzone® High Dose IM; Fluzone® High-Dose influenza vaccine; Seasonal influenza virus vaccine - sanofi pasteur

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 13 Oct 2016 Launched for Influenza virus infections (In the elderly, Prevention) in Canada (IM)
  • 24 Feb 2016 Registered for Influenza virus infections (In the elderly, Prevention) in Canada (IM)
  • 03 Aug 2015 Supplementary adverse events data from a phase IV trial for Influenza Virus infections released by Sanofi Pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top